Relief Therapeutics announces the renewal of a CHF 50 million share subscription agreement

Relief Therapeutics Holding SA, a biopharmaceutical company, has formalized the renewal of its CHF 50 million Share Subscription Facility (SSF) agreement with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited. This three-year extension highlights the continued support of GEM, a major shareholder of the company since 2016, for the development and strategic transformation of Relief. The agreement will allow Relief to strengthen its financial flexibility by periodically issuing shares to GEM, up to the total amount committed.

Under this renewed agreement, Relief benefits from the right to issue and sell ordinary shares to GEM for a cumulative amount of up to CHF 50 million, as needed and under pre-established conditions. In addition, GEM agreed to cancel a debt of CHF 1.37 million previously owed by Relief. As part of this re-engagement, Relief has promised the issuance of warrants to GEM, enabling the purchase of up to 3.35 million ordinary shares. The initiative is part of a process to strengthen Relief's financial foundations for the coming years.

Michelle Lock, Acting CEO of Relief, expressed her satisfaction with the renewal of this agreement, which represents a pillar for the stabilization and financial expansion of Relief in the medium term. At the same time, Relief continues the strategic reorientation of its activities, committing to a partnership model for the marketing of its products and increased focus on its research and development pipeline.